<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636411</url>
  </required_header>
  <id_info>
    <org_study_id>MD-164-2020</org_study_id>
    <nct_id>NCT04636411</nct_id>
  </id_info>
  <brief_title>Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes</brief_title>
  <official_title>Evaluation of the Effects of Oral Magnesium Supplementation on Glycemic Control and Inflammation Among Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samar Fares, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walaa Reda Abdel Fattah Mohamed Badr</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marwa Mostafa Ahmed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moushira Hosny Ezzelarab Sayed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagwa Eid Sobhy Saad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 74 Adult Patients with type 2 diabetes mellitus (T2D) will be enrolled and&#xD;
      randomized into 2 groups. The intervention group will receive oral magnesium (Mg)&#xD;
      supplementation. The study objectives are:&#xD;
&#xD;
        1. To estimate level of Mg (total and ionized) in patient with type 2 DM.&#xD;
&#xD;
        2. To determine the effect of Mg supplementation for diabetic patient on serum Mg level,&#xD;
           glycemic control and level of inflammation.&#xD;
&#xD;
        3. To assess the correlation between serum Mg level and glycemic control and level of&#xD;
           inflammatory mediators (CRP)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 74 Adult Patients of both genders who had been diagnosed with T2D and are on oral&#xD;
      anti-hyperglycemic drug and their HbA1C between 7and 8 %, will be enrolled in the study.&#xD;
      Initially the study protocol will be explained &amp; informed written consent will be obtained&#xD;
      from all participants. All subjects will be evaluated to ensure that they meet the&#xD;
      eligibility criteria through: Full history taking, complete physical examination and&#xD;
      investigations. the intervention group will receive oral magnesium (Mg) supplementation for 3&#xD;
      months (250 mg of elemental magnesium daily). The primary outcome is to determine the effect&#xD;
      of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of&#xD;
      inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study participants will be randomized into 2 groups (intervention and control group) to be studied simultaneously</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the effect of oral Mg supplementation for diabetic patient on Glycemic control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the effect of oral Mg supplementation for diabetic patient on inflammation (CRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum magnesium level</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the effect of Mg supplementation for diabetic patient on serum Mg level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hypomagnesemia</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>To estimate prevalence of hypomagnesemia in patients with type 2 DM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of serum Mg level</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>To assess the correlation between serum Mg level and glycemic control and level of inflammatory mediators (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total or ionized Mg</measure>
    <time_frame>3 months</time_frame>
    <description>Determine the more accurate measure for Mg in diabetic patient either total or ionized Mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive the standard care for diabetic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Magnesium Supplementation</intervention_name>
    <description>250 mg of elemental magnesium daily for three months</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care for diabetic patients</intervention_name>
    <description>Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes with HbA1C between 7 and 8%.&#xD;
&#xD;
          -  Both genders will be included in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on insulin.&#xD;
&#xD;
               -  Patients on diuretics or angiotensin-converting enzyme inhibitors in the last 2&#xD;
                  weeks.&#xD;
&#xD;
               -  Patients taking Mg containing supplements within 3 months.&#xD;
&#xD;
               -  Patients with significant gastrointestinal disorders (eg, chronic diarrhea).&#xD;
&#xD;
               -  Patients with impaired renal functions (eGFR&lt; 60 mL/min).&#xD;
&#xD;
               -  Heart block or heart failure&#xD;
&#xD;
               -  Patients treated with aldosterone antagonists.&#xD;
&#xD;
               -  Pregnant patients&#xD;
&#xD;
               -  Patients with evidence of infection.&#xD;
&#xD;
               -  Patients with chronic inflammatory conditions eg, SLE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagwa E Saad, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samar H Fares, Lecturer</last_name>
    <phone>01009403943</phone>
    <phone_ext>002</phone_ext>
    <email>Samar.fares@kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walaa R Badr, Specialist</last_name>
    <phone>01111787218</phone>
    <phone_ext>002</phone_ext>
    <email>walaareda84@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mokattam primary health care unit</name>
      <address>
        <city>Cairo</city>
        <state>Mokattam</state>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walaa R Badr, Specialist</last_name>
      <phone>01111787218</phone>
      <phone_ext>002</phone_ext>
      <email>walaareda84@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/30815575/</url>
    <description>Estimation of magnesium level in type 2 diabetes mellitus and its correlation with HbA1c level</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/31250127/</url>
    <description>Epigenetics and Type 2 Diabetes Risk</description>
  </link>
  <reference>
    <citation>Saeed H, Haj S, Qasim B. Estimation of magnesium level in type 2 diabetes mellitus and its correlation with HbA1c level. Endocrinol Diabetes Metab. 2018 Nov 2;2(1):e00048. doi: 10.1002/edm2.48. eCollection 2019 Jan.</citation>
    <PMID>30815575</PMID>
  </reference>
  <reference>
    <citation>Dhawan S, Natarajan R. Epigenetics and Type 2 Diabetes Risk. Curr Diab Rep. 2019 Jun 27;19(8):47. doi: 10.1007/s11892-019-1168-8. Review.</citation>
    <PMID>31250127</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 8, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Samar Fares, MD</investigator_full_name>
    <investigator_title>Lecturer of family medicine</investigator_title>
  </responsible_party>
  <keyword>Oral Magnesium</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Diabetes Control</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study data will be available upon reasonable request from central contact person</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After finalizing the study</ipd_time_frame>
    <ipd_access_criteria>The study data will be available upon reasonable request from central contact person</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

